Multistate model for the IELSG19 trial accounting for time of complete remission occurrence
| . | Transition, no CR → CR . | Transition, no CR → progression/death . | Transition, CR → progression/death . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| Double therapy vs single therapy, R-CLB vs R or CLB | 1.73 | 1.35-2.23 | <.001 | 1.03 | 0.63-1.67 | .91 | 0.54 | 0.33-0.89 | .02 |
| MALT-IPI score, high vs intermediate, or intermediate vs low | 0.65 | 0.54-0.78 | <.001 | 1.45 | 1.07-1.97 | .02 | 2.00 | 1.45-2.76 | <.001 |
| Time of transition to CR, y | — | — | — | — | — | — | 1.49 | 0.74-3.00 | .27 |
| . | Transition, no CR → CR . | Transition, no CR → progression/death . | Transition, CR → progression/death . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| Double therapy vs single therapy, R-CLB vs R or CLB | 1.73 | 1.35-2.23 | <.001 | 1.03 | 0.63-1.67 | .91 | 0.54 | 0.33-0.89 | .02 |
| MALT-IPI score, high vs intermediate, or intermediate vs low | 0.65 | 0.54-0.78 | <.001 | 1.45 | 1.07-1.97 | .02 | 2.00 | 1.45-2.76 | <.001 |
| Time of transition to CR, y | — | — | — | — | — | — | 1.49 | 0.74-3.00 | .27 |
CLB, chlorambucil; R, rituximab; R-CLB, rituximab + chlorambucil; MALT-IPI: mucosa-associated lymphoid tissue International Prognostic Index.